Non-Accredited Education
Understanding Collagen Dressings and their Benefit in Wound Care Complimentary Archived Webcast
Non-Accredited
Issue
- Issue:9
Honey: A Modern Wound Management Product
Edited by RJ White, RA Cooper, P Molan
- Issue:9
Disclosure: Mr. Cutting has acted as a paid consultancy for Medihoney and Dermasciences.
- Issue:9
Staphylococcus aureus has been known as a causative agent of infection since 1882 when Alexander Ogston identified its role in sepsis and abscess formation.1 It has continued to be one of the most recognized human pathogens throughout the community and hospital settings. S aureus is an opportunistic bacterium, which is frequently part of the human microflora, causing disease when the immune system becomes compromised. Although S aureus can be found in different parts of the body, the anterior nares are the primary ecological niche in humans.
- Issue:9
Disclosure: This work was supported by the ARRD (Associazione Romana Ricerca Dermatologica).
Acroangiodermatitis is a vasoproliferative disease of the lower limbs associated with congenital or acquired vascular alterations. It is clinically characterized by circumscribed, slowly-evolving, red violaceous or dusky macules, papules, or plaques.1,2
- Issue:9
Reconstruction of diabetic foot ulcers is often a challenging problem. The impairments involved with the healing process, along with the lack of resistance against infection in patients with diabetes, represent a familiar clinical problem.1 High treatment costs and unsatisfactory results are common.
- Issue:9
SANUWAVE™ ANNOUNCES APPROVAL FOR DIABETIC FOOT ULCER TREATMENT
SANUWAVE Inc (Alpharetta, Ga), a leading provider and developer of Pulsed Acoustic Cellular Expression (PACE™) technology, announces the company has received conditional approval from the US Food and Drug Administration (FDA) to initiate a multicenter, prospective, randomized clinical trial utilizing its dermaPACE™ device for the treatment of diabetic foot ulcers.
Press Release
ConvaTec and Boehringer Technologies Announce License Agreement
ConvaTec Acquires Exclusive Worldwide Rights for a Negative Pressure Wound Therapy System
SKILLMAN, NJ (December 18, 2008) — ConvaTec, a world-leading developer and marketer of innovative medical technologies for community and hospital care, announced today it has signed a long-term global exclusive license agreement with Boehringer Technologies to market and distribute Boehringer’s Engenex® Negative Pressure Wound Therapy (NPWT) System incorporating Bio-Dome™ Interface Technology.
WOUNDS News Wire
- Friday, December 5, 2008 - 15:08
- Wednesday, October 22, 2008 - 15:28
- Wednesday, October 22, 2008 - 15:25
CME Showcase
"Diabetic Peripheral Neuropathy"
Upcoming Accredited Webcast Release Date: December 22, 2008 Expiration Date: December 22, 2009 This activity is supported by an educational grant from PamLabs. To register for this Webcast, visit www.naccme.com/program/n-558/ |
"Current Concepts In Healing Chronic Diabetic Foot Ulcerations"
Upcoming Live Accredited Webcast with Q&A Noon to 1 p.m. EDT January 20, 2009 Rebroadcasts 7:30-8:30 p.m. EDT 3-4 p.m. EDT This activity is supported by an educational grant from Advanced Biohealing. To register for this Webcast, visit www.naccme.com/program/n-550/ |
| MRSA And Diabetic Foot Wounds: Where Do We Go From Here? Accredited Webcast Archive Version available now. This activity is supported by an educational grant from Pfizer. This activity is sponsored by the North American Center For Continuing Medical Education (NACCME). |
|
PERIPHERAL ARTERIAL DISEASE (PAD) AND CRITICAL LIMB ISCHEMIA (CLI): Managing Vascular and Wound Healing Challenges with Current and Emerging Technologies Maintenance Debridement: A New Look at Science and Art Accredited Webcast with Q&A: November 17, 2008 at 3:00pm EST This activity is supported by an educational grant from HealthPoint Ltd. |
REVIEW OUR OTHER
WOUND CARE BRANDS
Check out our other resources for healthcare professionals of all specialties.
